[go: up one dir, main page]

CO5540368A2 - Composicion de liberacion sostenida y proceso para producirla - Google Patents

Composicion de liberacion sostenida y proceso para producirla

Info

Publication number
CO5540368A2
CO5540368A2 CO03111730A CO03111730A CO5540368A2 CO 5540368 A2 CO5540368 A2 CO 5540368A2 CO 03111730 A CO03111730 A CO 03111730A CO 03111730 A CO03111730 A CO 03111730A CO 5540368 A2 CO5540368 A2 CO 5540368A2
Authority
CO
Colombia
Prior art keywords
sustained release
physiologically active
release composition
composition according
produce
Prior art date
Application number
CO03111730A
Other languages
English (en)
Inventor
Yamamoto Kazumichi
Akiko Yamada
Hata Yoshio
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26617908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5540368(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CO5540368A2 publication Critical patent/CO5540368A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Una composición de liberación sostenida que contiene un polímero de ácido láctico-ácido glicólico que tiene una relación de peso molecular medio en peso a pesomolecular medio en número de aproximadamente 1,90 ó menos, o una sal del mismo, y una sustancia fisiológicamente activa.2.- La composición de liberación sostenida de acuerdo con la reivindicación 1, donde la sustancia fisiológicamente activa es un péptido fisiológicamente activo.3.- La composición de liberación sostenida de acuerdo con la. reivindicación 2, donde la sustancia fisiológicamente activa es un derivado de la LH-RH.4.- La composición de liberación sostenida de acuerdo con la reivindicación 1, donde el peso molecular medio en peso de dicho polímero de ácido láctico-ácido glicólico es de aproximadamente 3.000 a aproximadamente 100.000.
CO03111730A 2001-06-29 2003-12-22 Composicion de liberacion sostenida y proceso para producirla CO5540368A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001199462 2001-06-29
JP2001340980 2001-11-06

Publications (1)

Publication Number Publication Date
CO5540368A2 true CO5540368A2 (es) 2005-07-29

Family

ID=26617908

Family Applications (1)

Application Number Title Priority Date Filing Date
CO03111730A CO5540368A2 (es) 2001-06-29 2003-12-22 Composicion de liberacion sostenida y proceso para producirla

Country Status (31)

Country Link
US (3) US20040241229A1 (es)
EP (2) EP1399133B2 (es)
JP (3) JP5491318B2 (es)
KR (3) KR20090096755A (es)
CN (1) CN1535141B (es)
AR (1) AR034640A1 (es)
AT (1) ATE429903T1 (es)
AU (1) AU2002311630B2 (es)
BR (1) BR0210572A (es)
CA (1) CA2451718C (es)
CO (1) CO5540368A2 (es)
CY (1) CY1109272T1 (es)
CZ (1) CZ306388B6 (es)
DE (1) DE60232147D1 (es)
DK (1) DK1399133T4 (es)
ES (1) ES2324156T5 (es)
HU (1) HU230152B1 (es)
IL (1) IL159060A0 (es)
MX (1) MXPA03011440A (es)
MY (1) MY139606A (es)
NO (1) NO333531B1 (es)
NZ (1) NZ529968A (es)
PE (1) PE20030069A1 (es)
PL (1) PL212531B1 (es)
PT (1) PT1399133E (es)
RU (2) RU2297240C2 (es)
SI (1) SI1399133T2 (es)
SK (1) SK287568B6 (es)
TW (1) TWI225416B (es)
WO (1) WO2003002091A2 (es)
ZA (1) ZA200309153B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2490351C (en) 2002-06-25 2011-11-01 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
DE60315472T2 (de) * 2002-09-24 2008-04-30 Asahi Kasei Chemicals Corp. Glycolsaüre copolymer und verfahren zu dessen herstellung
TW200529890A (en) 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
DE602006000381T2 (de) * 2005-04-28 2008-12-18 Nipro Corp., Osaka Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer
DK1984009T3 (da) 2006-01-18 2013-01-28 Qps Llc Farmaceutiske sammensætninger med forbedret stabilitet
CN101563068B (zh) * 2006-12-18 2013-03-20 武田药品工业株式会社 缓释组合物和其制备方法
DK3660073T3 (da) 2007-02-15 2023-09-18 Tolmar International Ltd Poly(lactid-co-glycolid) med lav sprængning
KR101008462B1 (ko) * 2007-07-26 2011-01-14 조남열 치어류 이동용 어도 장치
KR100969641B1 (ko) * 2007-11-12 2010-07-14 민선영 저수지의 제방용 어도
KR100969642B1 (ko) * 2007-11-15 2010-07-12 민선영 하천의 보용 어도
TWI477266B (zh) * 2009-11-05 2015-03-21 Taiwan Biotech Co Ltd 連續製備微粒的方法、裝置及其收集單元
US8641900B2 (en) 2009-11-05 2014-02-04 Taiwan Biotech Co., Ltd Method and device for continuously preparing microspheres, and collection unit thereof
EP2697361A1 (en) * 2011-04-11 2014-02-19 Cellcura Asa Protein-free culture media products for manufacturing viral-based vaccines
US9517210B2 (en) 2012-07-12 2016-12-13 Takeda Pharmaceutical Company Limited Method for producing microcapsule powder
RU2572992C2 (ru) * 2012-08-28 2016-01-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курская государственная сельскохозяйственная академия имени И.И. Иванова" Способ получения микрокапсул водорастворимых препаратов пестицидов
JP5959728B2 (ja) 2013-04-11 2016-08-02 三井化学株式会社 乳酸―グリコール酸共重合体の製造法またはその塩の製造法
RU2537173C1 (ru) * 2013-05-24 2014-12-27 Александр Александрович Кролевец Способ получения микрокапсул гетероциклических соединений триазинового ряда
RU2537248C1 (ru) * 2013-05-24 2014-12-27 Екатерина Евгеньевна Быковская Способ получения микрокапсул гетероциклических соединений триазинового ряда
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
EP3131532A1 (de) 2014-04-16 2017-02-22 Veyx-Pharma GmbH Veterinärpharmazeutische zusammensetzung und deren verwendung
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
CN104224731A (zh) * 2014-09-11 2014-12-24 北京天晟泰丰医药科技有限公司 一种不含致敏性辅料的九肽微球的制备方法
JP5938762B1 (ja) 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN110856690B (zh) * 2018-08-22 2024-07-02 深圳善康医药科技股份有限公司 一种植入剂包膜及干燥装置
WO2021234731A1 (en) * 2020-05-18 2021-11-25 Dr Reddy's Institute Of Life Sciences Sustained release compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JPH0720859B2 (ja) 1985-02-07 1995-03-08 武田薬品工業株式会社 マイクロカプセルの製造法
EP0190833B1 (en) 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
EP0480918A1 (en) 1988-02-10 1992-04-22 Abbott Laboratories Reduced size lhrh analogs
US5110904A (en) 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
JP3200706B2 (ja) 1990-04-13 2001-08-20 武田薬品工業株式会社 生体内分解型高分子重合物
DE69129770T2 (de) * 1990-04-13 1998-11-19 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung
CA2079509C (en) * 1991-10-01 2002-05-14 Shigeyuki Takada Prolonged release microparticle preparation and production of the same
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
JP3761594B2 (ja) * 1993-07-05 2006-03-29 武田薬品工業株式会社 徐放性製剤の製造法
JPH08259460A (ja) 1995-01-23 1996-10-08 Takeda Chem Ind Ltd 徐放性製剤の製造法
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
JPH11269094A (ja) 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
US6740634B1 (en) * 1998-01-16 2004-05-25 Takeda Chemical Industries, Ltd. Sustained release compositions, process for producing the same and utilization thereof
CN1134479C (zh) † 1998-12-15 2004-01-14 武田药品工业株式会社 制备聚合物的方法
JP3716146B2 (ja) * 1998-12-15 2005-11-16 武田薬品工業株式会社 ポリマーの製造方法
JP2002114667A (ja) 2000-10-11 2002-04-16 Ltt Institute Co Ltd 徐放性製剤用組成物、その製造法および徐放性マイクロカプセル製剤
TW200526267A (en) * 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
CA2490351C (en) * 2002-06-25 2011-11-01 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition

Also Published As

Publication number Publication date
TWI225416B (en) 2004-12-21
HK1061802A1 (en) 2004-10-08
HUP0400382A3 (en) 2010-01-28
JP5931147B2 (ja) 2016-06-08
CA2451718C (en) 2011-03-15
NO333531B1 (no) 2013-07-01
US20040241229A1 (en) 2004-12-02
EP1399133A2 (en) 2004-03-24
AU2002311630B2 (en) 2007-07-19
PT1399133E (pt) 2009-06-05
MY139606A (en) 2009-10-30
DK1399133T3 (da) 2009-08-03
SK287568B6 (sk) 2011-02-04
US20120295848A1 (en) 2012-11-22
JP2012136530A (ja) 2012-07-19
RU2004102503A (ru) 2005-03-10
PL212531B1 (pl) 2012-10-31
CA2451718A1 (en) 2003-01-09
CY1109272T1 (el) 2014-07-02
DK1399133T4 (da) 2012-07-23
ES2324156T5 (es) 2012-07-23
BR0210572A (pt) 2004-08-03
EP1399133B2 (en) 2012-05-02
JP2010280703A (ja) 2010-12-16
IL159060A0 (en) 2004-05-12
JP5860300B2 (ja) 2016-02-16
WO2003002091A3 (en) 2003-07-24
KR20090108640A (ko) 2009-10-15
AR034640A1 (es) 2004-03-03
NO20035737L (no) 2004-02-20
KR100988178B1 (ko) 2010-10-18
EP1399133B1 (en) 2009-04-29
EP2108363A1 (en) 2009-10-14
CZ20033492A3 (cs) 2005-01-12
NZ529968A (en) 2005-08-26
PL367491A1 (en) 2005-02-21
WO2003002091A2 (en) 2003-01-09
DE60232147D1 (de) 2009-06-10
SI1399133T2 (sl) 2012-08-31
RU2297240C2 (ru) 2007-04-20
KR20090096755A (ko) 2009-09-14
ATE429903T1 (de) 2009-05-15
JP2015007120A (ja) 2015-01-15
KR20040018401A (ko) 2004-03-03
HU230152B1 (hu) 2015-09-28
MXPA03011440A (es) 2004-07-01
CN1535141A (zh) 2004-10-06
RU2006143104A (ru) 2008-06-20
PE20030069A1 (es) 2003-03-17
RU2434644C2 (ru) 2011-11-27
HUP0400382A2 (hu) 2004-12-28
US20080108778A1 (en) 2008-05-08
ES2324156T3 (es) 2009-07-31
CZ306388B6 (cs) 2017-01-04
ZA200309153B (en) 2005-01-26
SI1399133T1 (sl) 2009-10-31
CN1535141B (zh) 2013-04-24
JP5491318B2 (ja) 2014-05-14
US8258252B2 (en) 2012-09-04
NO20035737D0 (no) 2003-12-19
SK15612003A3 (sk) 2004-07-07

Similar Documents

Publication Publication Date Title
CO5540368A2 (es) Composicion de liberacion sostenida y proceso para producirla
CO5540367A2 (es) Composicion de liberacion controlada y metodo para producirla
BRPI0210722B8 (pt) implantes injetáveis biodegradáveis e métodos relacionados de produção e uso
NO20034359L (no) Höystyrke bioresorberbare sammensetninger som inneholder polyglykolsyre
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
PL358103A1 (pl) Hydrofilowe molekularne roztwory dyspersyjne karwedilolu
DE59309388D1 (de) Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
ATE337357T1 (de) Negativ geladenes amphiphiles blockcopolymer als arzneistoffträger und komplex davon mit postitiv geladenem arzneistoff
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
ATE287705T1 (de) Wärmegellierende bioabbaubare wässrige polymerlösung
PE20110236A1 (es) Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
NO20092662L (no) Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme
ATE365183T1 (de) Positiv geladenes amphiphiles blockcopolymer als arzneistoffträger und komplex davon mit negativ geladenem arzneistoff
ATE427737T1 (de) Mikroemulsionen von retinoiden und diese enthaltende pharmazeutische zusammensetzungen
AR031649A1 (es) Composicion farmaceutica de dronedarona para administracion parenteral
CY1105020T1 (el) Υποκαταστατες διαζεπανες
AR033918A1 (es) Composicion para acelerar la soldadura de una fractura osea
NO20052505L (no) Ny bruk av dextran-sulfat
AR034044A1 (es) Composicion para el tratamiento reconstituyente en enfermedades de cartilago
NO20024363L (no) Nye LHRH-antagonister, produksjon og anvendelse av disse som medikamant
TW200613012A (en) Sustained-release composition, process for producing the same and use of the same
SE0001916D0 (sv) Novel formulation
ES2185373T3 (es) Encapsulacion de peptidos solubles en agua.

Legal Events

Date Code Title Description
FC Application refused